Arena Pharmaceuticals (ARNA) 3.59 $ARNA
Technical Coverage on Biotech Stocks - Arena Pharma, XOMA, Dyax, Mast Therapeutics, and Tekmira Pharma
PR Newswire - Fri Jan 02, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 31, 2014, the NASDAQ Composite ended at 4,736.05, down 0.87%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 17,823.07, and the S&P 500 closed at 2,058.90, down 1.03%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 791.97, down 0.98%, while the index has advanced 7.03% in the previous three months. Register for your complimentary reports on these five stocks at:
MSTX: 0.57 (+0.01), TKMR: 14.76 (-0.39), ARNA: 3.59 (+0.12), DYAX: 14.11 (+0.05), XOMA: 3.55 (-0.04)
Sell EnteroMedics And Step To The Sidelines
Scientist on Stocks - at Seeking Alpha - Tue Dec 30, 11:25AM CST
OREX: 6.30 (+0.24), ETRM: 1.49 (+0.07), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
Can High Priced Novo Nordisk Anti-Obesity Injection Make It?
Spencer Osborne - at Seeking Alpha - Mon Dec 29, 12:30PM CST
OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
The Obesity Treatment Market Could Finally Achieve Some Of Its Potential In 2015
Kanak Kanti De - at Seeking Alpha - Mon Dec 29, 12:24PM CST
OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
Arena - Belviq Advertsing Closes Out Year With Big Push
Spencer Osborne - at Seeking Alpha - Mon Dec 29, 12:13PM CST
OREX: 6.30 (+0.24), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
Is Vivus Headed Towards An Unfortunate Ending?
Alexander Maxwell - at Seeking Alpha - Sat Dec 27, 7:27AM CST
OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
The Newest FDA-Approved Obesity Drug Is Also the Oldest
Brian Orelli, The Motley Fool - Motley Fool - Sat Dec 27, 7:04AM CST
Novo Nordisk on Tuesday gained Food and Drug Administration approval for its obesity drug Saxenda. While that is not the feat it would have been a few years ago, Novo Nordisk can boast that its obesity drug was approved on its first try, unlike ...
OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), AZN: 70.40 (+0.02), VVUS: 3.06 (+0.18), LLY: 70.06 (+1.07), GSK: 42.37 (-0.37), ARNA: 3.59 (+0.12)
3 Stocks Poised for Eye-Popping Gains in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Dec 27, 6:27AM CST
Source: Flicker via 401kcalculator.org The stock market has been on fire since the start of 2012. Biotech companies, though, have posted particularly impressive gains, markedly outperforming the broader markets during this time period. The ...
OREX: 6.30 (+0.24), GILD: 94.91 (+0.65), VVUS: 3.06 (+0.18), IBB: 306.34 (+2.99), ABBV: 65.89 (+0.45), PRTA: 20.35 (-0.41), ARNA: 3.59 (+0.12)
4 Potential Blockbuster Drugs The FDA Just Approved
at Investor's Business Daily - Fri Dec 26, 11:35AM CST
While the approval of AbbVie's (ABBV) hepatitis C regimen Viekira Pak hogged most of the headlines, over the past week the FDA has approved a whole passel of medicines that could be blockbusters for their makers. Here's a short list of some of the...
OREX: 6.30 (+0.24), MYGN: 34.61 (+0.55), NVO: 42.49 (+0.17), CBST: 100.76 (+0.11), AZN: 70.40 (+0.02), MRK: 57.19 (+0.40), VVUS: 3.06 (+0.18), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48), ARNA: 3.59 (+0.12)
First Week Of March 2015 Options Trading For Arena Pharmaceuticals
at The Street - Fri Dec 26, 10:32AM CST
Investors in Arena Pharmaceuticals Inc saw new options become available this week, for the March 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 84 days until expiration...
ARNA: 3.59 (+0.12)
Arena Pharmaceuticals (ARNA): Today's Weak On High Volume Stock
at The Street - Fri Dec 26, 9:22AM CST
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate
ARNA: 3.59 (+0.12)
Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:20PM CST
Novo Nordisk's (NVO) Saxenda received FDA approval as the first once-daily human glucagon-like peptide-1 analogue for chronic weight management.
OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), ARNA: 3.59 (+0.12)
3 Biotech Stocks I Don't Want for Christmas
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 24, 7:50AM CST
With 2014 drawing to a close, biotech investors are probably wondering which stocks to stuff in their stockings for next year. While there are plenty of promising biotech stocks to choose from, we should also take note of three high-risk,...
ENDP: 72.15 (+0.03), INO: 9.32 (+0.14), ZGNX: 1.42 (+0.05), PFE: 31.33 (+0.18), AUXL: 34.47 (+0.09), VVUS: 3.06 (+0.18), TEVA: 56.22 (-1.29), ARNA: 3.59 (+0.12)
Novo Nordisk Enters Anti-Obesity Space With New FDA Approval
Spencer Osborne - at Seeking Alpha - Wed Dec 24, 6:46AM CST
ZFGN: 30.92 (+0.08), OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
FDA clears Novo Nordisk's weight loss drug Saxenda
AP - Tue Dec 23, 3:49PM CST
NEW YORK (AP) — The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. It's the first injectable drug approved for weight loss.
OREX: 6.30 (+0.24), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
FDA clears Novo weight management drug
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:05PM CST
OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
Contrave Prescriptions Still Rising In A Down Week
Clinically Sound Investor - at Seeking Alpha - Mon Dec 22, 2:47PM CST
OREX: 6.30 (+0.24), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
Orexigen - Contrave Script Numbers Remain Impressive
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:31PM CST
OREX: 6.30 (+0.24), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
Belviq Scripts Dip - Lack Of T.V. Ads Will Impact Next Numbers
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:27PM CST
OREX: 6.30 (+0.24), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
Technical Coverage on Biotech Stocks - Arena Pharma, XOMA, Dyax, Mast Therapeutics, and Tekmira Pharma
PR Newswire - Fri Jan 02, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 31, 2014, the NASDAQ Composite ended at 4,736.05, down 0.87%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 17,823.07, and the S&P 500 closed at 2,058.90, down 1.03%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 791.97, down 0.98%, while the index has advanced 7.03% in the previous three months. Register for your complimentary reports on these five stocks at:
MSTX: 0.57 (+0.01), TKMR: 14.76 (-0.39), ARNA: 3.59 (+0.12), DYAX: 14.11 (+0.05), XOMA: 3.55 (-0.04)
Sell EnteroMedics And Step To The Sidelines
Scientist on Stocks - at Seeking Alpha - Tue Dec 30, 11:25AM CST
OREX: 6.30 (+0.24), ETRM: 1.49 (+0.07), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
Can High Priced Novo Nordisk Anti-Obesity Injection Make It?
Spencer Osborne - at Seeking Alpha - Mon Dec 29, 12:30PM CST
OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
The Obesity Treatment Market Could Finally Achieve Some Of Its Potential In 2015
Kanak Kanti De - at Seeking Alpha - Mon Dec 29, 12:24PM CST
OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
Arena - Belviq Advertsing Closes Out Year With Big Push
Spencer Osborne - at Seeking Alpha - Mon Dec 29, 12:13PM CST
OREX: 6.30 (+0.24), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
Is Vivus Headed Towards An Unfortunate Ending?
Alexander Maxwell - at Seeking Alpha - Sat Dec 27, 7:27AM CST
OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
The Newest FDA-Approved Obesity Drug Is Also the Oldest
Brian Orelli, The Motley Fool - Motley Fool - Sat Dec 27, 7:04AM CST
Novo Nordisk on Tuesday gained Food and Drug Administration approval for its obesity drug Saxenda. While that is not the feat it would have been a few years ago, Novo Nordisk can boast that its obesity drug was approved on its first try, unlike ...
OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), AZN: 70.40 (+0.02), VVUS: 3.06 (+0.18), LLY: 70.06 (+1.07), GSK: 42.37 (-0.37), ARNA: 3.59 (+0.12)
3 Stocks Poised for Eye-Popping Gains in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Dec 27, 6:27AM CST
Source: Flicker via 401kcalculator.org The stock market has been on fire since the start of 2012. Biotech companies, though, have posted particularly impressive gains, markedly outperforming the broader markets during this time period. The ...
OREX: 6.30 (+0.24), GILD: 94.91 (+0.65), VVUS: 3.06 (+0.18), IBB: 306.34 (+2.99), ABBV: 65.89 (+0.45), PRTA: 20.35 (-0.41), ARNA: 3.59 (+0.12)
4 Potential Blockbuster Drugs The FDA Just Approved
at Investor's Business Daily - Fri Dec 26, 11:35AM CST
While the approval of AbbVie's (ABBV) hepatitis C regimen Viekira Pak hogged most of the headlines, over the past week the FDA has approved a whole passel of medicines that could be blockbusters for their makers. Here's a short list of some of the...
OREX: 6.30 (+0.24), MYGN: 34.61 (+0.55), NVO: 42.49 (+0.17), CBST: 100.76 (+0.11), AZN: 70.40 (+0.02), MRK: 57.19 (+0.40), VVUS: 3.06 (+0.18), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48), ARNA: 3.59 (+0.12)
First Week Of March 2015 Options Trading For Arena Pharmaceuticals
at The Street - Fri Dec 26, 10:32AM CST
Investors in Arena Pharmaceuticals Inc saw new options become available this week, for the March 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 84 days until expiration...
ARNA: 3.59 (+0.12)
Arena Pharmaceuticals (ARNA): Today's Weak On High Volume Stock
at The Street - Fri Dec 26, 9:22AM CST
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate
ARNA: 3.59 (+0.12)
Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:20PM CST
Novo Nordisk's (NVO) Saxenda received FDA approval as the first once-daily human glucagon-like peptide-1 analogue for chronic weight management.
OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), ARNA: 3.59 (+0.12)
3 Biotech Stocks I Don't Want for Christmas
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 24, 7:50AM CST
With 2014 drawing to a close, biotech investors are probably wondering which stocks to stuff in their stockings for next year. While there are plenty of promising biotech stocks to choose from, we should also take note of three high-risk,...
ENDP: 72.15 (+0.03), INO: 9.32 (+0.14), ZGNX: 1.42 (+0.05), PFE: 31.33 (+0.18), AUXL: 34.47 (+0.09), VVUS: 3.06 (+0.18), TEVA: 56.22 (-1.29), ARNA: 3.59 (+0.12)
Novo Nordisk Enters Anti-Obesity Space With New FDA Approval
Spencer Osborne - at Seeking Alpha - Wed Dec 24, 6:46AM CST
ZFGN: 30.92 (+0.08), OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
FDA clears Novo Nordisk's weight loss drug Saxenda
AP - Tue Dec 23, 3:49PM CST
NEW YORK (AP) — The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. It's the first injectable drug approved for weight loss.
OREX: 6.30 (+0.24), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
FDA clears Novo weight management drug
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:05PM CST
OREX: 6.30 (+0.24), NVO: 42.49 (+0.17), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
Contrave Prescriptions Still Rising In A Down Week
Clinically Sound Investor - at Seeking Alpha - Mon Dec 22, 2:47PM CST
OREX: 6.30 (+0.24), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
Orexigen - Contrave Script Numbers Remain Impressive
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:31PM CST
OREX: 6.30 (+0.24), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
Belviq Scripts Dip - Lack Of T.V. Ads Will Impact Next Numbers
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:27PM CST
OREX: 6.30 (+0.24), VVUS: 3.06 (+0.18), ARNA: 3.59 (+0.12)
